Can Fite Biopharma Ltd (CANF) — Working Capital to Net Assets Ratio
Can Fite Biopharma Ltd (CANF) has a Working Capital to Net Assets ratio of 120.0% as of December 2025. Working capital of ILA6.71 Million (current assets of ILA9.44 Million minus current liabilities of ILA2.73 Million) is measured against net assets of ILA5.59 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See how leveraged is Can Fite Biopharma Ltd's balance sheet to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Can Fite Biopharma Ltd Working Capital to Net Assets (2011–2025)
This chart shows how Can Fite Biopharma Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of December 2025, the ratio stands at 120.0%, reflecting working capital of ILA6.71 Million against net assets of ILA5.59 Million ILA. Check CANF tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Can Fite Biopharma Ltd (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Can Fite Biopharma Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see how much is Can Fite Biopharma Ltd worth.
| Year | WC/NA Ratio | Working Capital (ILA) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 120.0% | ILA6.71 Million | ILA5.59 Million | ILA9.44 Million | ILA2.73 Million | ▼ -7.5 pp |
| 2024 | 127.5% | ILA6.93 Million | ILA5.44 Million | ILA8.98 Million | ILA2.05 Million | ▲ +1.1 pp |
| 2023 | 126.3% | ILA7.89 Million | ILA6.24 Million | ILA9.91 Million | ILA2.02 Million | ▼ -22.5 pp |
| 2022 | 148.8% | ILA6.66 Million | ILA4.47 Million | ILA9.16 Million | ILA2.50 Million | ▲ +28.3 pp |
| 2021 | 120.6% | ILA17.34 Million | ILA14.38 Million | ILA20.07 Million | ILA2.73 Million | ▼ -13.3 pp |
| 2020 | 133.9% | ILA8.13 Million | ILA6.07 Million | ILA9.40 Million | ILA1.27 Million | ▼ -24.7 pp |
| 2019 | 158.6% | ILA3.87 Million | ILA2.44 Million | ILA7.14 Million | ILA3.27 Million | ▼ -0.1 pp |
| 2018 | 158.7% | ILA4.78 Million | ILA3.02 Million | ILA7.90 Million | ILA3.12 Million | ▼ -7.3 pp |
| 2017 | 166.0% | ILA5.07 Million | ILA3.05 Million | ILA6.87 Million | ILA1.80 Million | ▼ -30.2 pp |
| 2016 | 196.2% | ILA7.60 Million | ILA3.87 Million | ILA10.10 Million | ILA2.50 Million | ▲ +45.4 pp |
| 2015 | 150.8% | ILA15.76 Million | ILA10.44 Million | ILA17.53 Million | ILA1.78 Million | ▲ +24.5 pp |
| 2014 | 126.3% | ILA8.66 Million | ILA6.86 Million | ILA10.15 Million | ILA1.48 Million | ▲ +26.7 pp |
| 2013 | 99.7% | ILA4.44 Million | ILA4.46 Million | ILA6.58 Million | ILA2.14 Million | ▼ -3.7 pp |
| 2012 | 103.4% | ILA-732.35K | ILA-707.99K | ILA1.59 Million | ILA2.32 Million | ▼ -2.2 pp |
| 2011 | 105.6% | ILA3.48 Million | ILA3.29 Million | ILA4.83 Million | ILA1.35 Million | — |